In the fiscal year 2022, the number of quasi-drugs approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan amounted to approximately two thousand. PMDA functions as a regulatory agency for pharmaceutical products and medical devices, working together with the health ministry in Japan.
Number of quasi-drugs approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan from fiscal year 2013 to 2022
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$149 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Number of BTC and OTC drugs approved by PMDA Japan FY 2013-2022
- Premium Statistic Number of prescription drugs approved by PMDA Japan FY 2015-2022, by type
- Premium Statistic Number of in vitro diagnostics approved by PMDA Japan FY 2013-2022
- Premium Statistic Number of pharmaceutical products approved by PMDA Japan FY 2022, by type
- Premium Statistic Number of new drugs approved by PMDA Japan FY 2014-2022
- Premium Statistic Number of NME approved Japan 2013-2022
- Premium Statistic Number of biosimilars approved by PMDA Japan 2010-2019
- Premium Statistic Number of novel drugs approved annually by CDER 2008-2022
- Premium Statistic Number of biological drugs approved Japan 2012-2021
- Basic Statistic Number of FDA approved NMEs, 2009-2018, by size of drug owner
About the region
10
- Premium Statistic Number of newly approved medical devices Japan FY 2014-2022, by category
- Premium Statistic Number of approved generic medical devices Japan FY 2013-2022, by year of submiss
- Premium Statistic Number of approved new medical devices Japan FY 2013-2022, by year of submission
- Premium Statistic Meiji's pharmaceutical business net sales FY 2013-2022
- Premium Statistic Biosimilar market size Japan 2018-2030
- Premium Statistic Total asset of major companies in pharmaceutical industry Japan 2023
- Premium Statistic Noevir's operating income FY 2015-2019
- Premium Statistic Pharmaceutical market size Japan 2008-2015
- Premium Statistic Biopharmaceutical market size forecast Japan 2011-2020
- Premium Statistic Hair remedies production amount in Japan 2021, by item
Selected statistics
6
- Premium Statistic Medicinal market growth worldwide including rebates 2009-2018
- Basic Statistic AstraZeneca's revenue from top product Pulmicort 2006-2022
- Premium Statistic Expenditure worldwide on diabetes by market 2013-2018
- Premium Statistic Standard Unit medicine use per capita in the U.S. 2007-2011
- Premium Statistic Chinese insulin market distribution: leading companies 2011
- Premium Statistic U.S. insulin market distribution: leading companies 2011
Other regions
10
- Basic Statistic Number of new and expired active substances in Norway 2013-2021
- Premium Statistic Genomma Lab: headcount 2015-2019
- Premium Statistic Value added of the pharmaceutical industry in Italy 2000-2022
- Premium Statistic Revenue from pharmaceutical manufacturer in Denmark 2009-2022
- Basic Statistic Key measurements of U.S. CDER drug approvals in 2022
- Basic Statistic Sales value of generic pharmaceuticals in Sweden 2013-2022
- Premium Statistic Sales revenue Hanmi Pharmaceutical 2017-2022
- Premium Statistic Unit market share of vitamins sold in Spain by company 2019-2020
- Premium Statistic Industry turnover for leading pharmaceuticals German 2017
- Premium Statistic Physicians that received opioid-manufacturer payments in New York 2013-2015
Related statistics
10
- Premium Statistic Quasi drugs production value in Japan 2012-2021
- Premium Statistic Quasi drugs production value in Japan 2021, by therapeutic category
- Premium Statistic Breakdown of quasi-drugs production in Japan 2021, by therapeutic category
- Premium Statistic Fuji Pharma's sales distribution FY 2022, by therapeutic category
- Premium Statistic Sawai Pharmaceutical's employee numbers 2012-2021
- Basic Statistic Fuji Pharma's net sales FY 2013-2022
- Premium Statistic Fuji Pharma's R&D costs FY 2013-2022
- Premium Statistic Fuji Pharma's total assets FY 2013-2022
- Basic Statistic Takeda Pharmaceutical's revenue FY 2013-2022
- Premium Statistic Major drug manufacturers Japan FY 2020, by wholesalers' sales share
Further related statistics
10
- Sanofi's total assets 2007-2022
- Merck & Co - expenditure on research and development 2006-2022
- Merck & Co total assets 2009-2022
- Merck & Co cash dividends declared 2006-2022
- Pfizer's revenues in the U.S. and abroad 2009-2022
- Pfizer's ad spending 2008-2022
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
- Revenue of Sinopharm 2011-2022, by category
- MorphoSys' research & development expenditure 2006-2022
Further Content: You might find this interesting as well
Statistics
- Sanofi's total assets 2007-2022
- Merck & Co - expenditure on research and development 2006-2022
- Merck & Co total assets 2009-2022
- Merck & Co cash dividends declared 2006-2022
- Pfizer's revenues in the U.S. and abroad 2009-2022
- Pfizer's ad spending 2008-2022
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
- Revenue of Sinopharm 2011-2022, by category
- MorphoSys' research & development expenditure 2006-2022
PMDA. (September 14, 2023). Number of quasi-drugs approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan from fiscal year 2013 to 2022 [Graph]. In Statista. Retrieved December 07, 2023, from https://www.statista.com/statistics/827333/japan-pmda-number-approved-quasi-drugs/
PMDA. "Number of quasi-drugs approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan from fiscal year 2013 to 2022." Chart. September 14, 2023. Statista. Accessed December 07, 2023. https://www.statista.com/statistics/827333/japan-pmda-number-approved-quasi-drugs/
PMDA. (2023). Number of quasi-drugs approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan from fiscal year 2013 to 2022. Statista. Statista Inc.. Accessed: December 07, 2023. https://www.statista.com/statistics/827333/japan-pmda-number-approved-quasi-drugs/
PMDA. "Number of Quasi-drugs Approved by The Pharmaceuticals and Medical Devices Agency (Pmda) in Japan from Fiscal Year 2013 to 2022." Statista, Statista Inc., 14 Sep 2023, https://www.statista.com/statistics/827333/japan-pmda-number-approved-quasi-drugs/
PMDA, Number of quasi-drugs approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan from fiscal year 2013 to 2022 Statista, https://www.statista.com/statistics/827333/japan-pmda-number-approved-quasi-drugs/ (last visited December 07, 2023)
Number of quasi-drugs approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan from fiscal year 2013 to 2022 [Graph], PMDA, September 14, 2023. [Online]. Available: https://www.statista.com/statistics/827333/japan-pmda-number-approved-quasi-drugs/